GlassScriptPhysician profile
Tahseen Qadeer
NPI 1528096229
$5,794.60
in general payments reported to CMS, 2019-2025
37 companies · $597 in 2025
The $597 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $771 · 2021: $1,052 · 2022: $853 · 2023: $837 · 2024: $419 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.48 | 2019-2024 | |
| Daiichi Sankyo INC. | $421.69 | 2019-2023 | Injectafer |
| Smith+Nephew, INC. | $407.73 | 2019-2024 | Pico 7 |
| Evofem Biosciences, INC. | $407.66 | 2021-2025 | Phexxi, Solosec, Phexx |
| Lupin INC. | $380.56 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $362.38 | 2022-2024 | |
| Hologic Sales and Service, LLC | $306.93 | 2019-2025 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Astellas Pharma US INC | $296.54 | 2023-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $259.98 | 2021-2022 | |
| Pfizer INC. | $256.64 | 2019-2025 | |
| Therapeuticsmd, INC. | $225.02 | 2020-2022 | |
| Coopersurgical, INC. | $198.85 | 2019-2023 | Advincula Delineator Uterine Manipulator |
| Merck Sharp & Dohme LLC | $178.20 | 2019-2025 | Gardasil 9, Gardasil |
| Roche Diagnostics Corporation | $165.33 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.97 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $164.07 | 2023-2025 | Myfembree, Gemtesa |
| Agile Therapeutics, INC. | $118.97 | 2022-2023 | Twirla |
| Exact Sciences Corporation | $84.72 | 2023-2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $81.72 | 2024-2025 | Slynd, Nuvessa |
| Avion Pharmaceuticals | $69.71 | 2021-2023 | Balcoltra |
| Pacira Pharmaceuticals Incorporated | $59.39 | 2019-2021 | |
| Allergan, INC. | $58.63 | 2019 | |
| Covidien LP | $55.58 | 2019 | |
| Organon LLC | $46.36 | 2021-2023 | Nexplanon |
| Aspira Women'S Health INC | $42.90 | 2020 | |
| Shield Therapeutics INC | $38.98 | 2022-2023 | Accrufer |
| Biom'Up France Sas | $37.21 | 2020-2021 | |
| Cepheid | $36.86 | 2025 | Genexpert |
| Scynexis, INC. | $30.31 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $28.42 | 2024-2025 | Kristalose |
| Mission Pharmacal Company | $27.65 | 2023-2024 | Citranatal, Citranatal Medley |
| Gilead Sciences, INC. | $23.02 | 2019 | |
| Meditrina | $19.57 | 2023 | |
| Ferring Pharmaceuticals INC. | $17.08 | 2019 | |
| Sage Therapeutics, LLC | $15.59 | 2021 | |
| Minerva Surgical, INC | $15.14 | 2019 | |
| Kesin Pharma Corporation | $14.76 | 2023 | Likmez |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tahseen Qadeer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.